Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 7, 2015, to announce its financial results for the first quarter ended March 31, 2015. This filing primarily serves to furnish the press release detailing these results, which is included as an exhibit. Investors looking for specific financial performance metrics, revenue figures, or details on operational progress would need to refer to the press release itself (Exhibit 99.1) for this information. The 8-K filing itself does not contain the detailed financial data but acts as the official notification of its public release.
Key Highlights
- 1Alnylam Pharmaceuticals announced its financial results for the quarter ended March 31, 2015, via an 8-K filing.
- 2The primary purpose of the filing is to furnish the accompanying press release containing the detailed financial results.
- 3The press release, dated May 7, 2015, is attached as Exhibit 99.1.
- 4This 8-K filing does not contain the specific financial figures but directs investors to the press release for those details.
- 5The information furnished is not deemed 'filed' for purposes of Section 18 of the Exchange Act, meaning it doesn't carry the same legal liabilities as a formally filed document unless specifically incorporated by reference.
- 6The filing confirms the company's principal executive offices are located at 300 Third Street, Cambridge, MA 02142.
Frequently Asked Questions
The main purpose of this 8-K filing is to formally announce and provide access to Alnylam Pharmaceuticals' financial results for the first quarter ended March 31, 2015. The detailed financial information is presented in a press release that is furnished as an exhibit to this report.
The specific financial results, including revenue, expenses, and other key performance indicators for the quarter ended March 31, 2015, can be found in the press release dated May 7, 2015, which is included as Exhibit 99.1 to this Form 8-K filing.
This specific 8-K filing primarily serves to announce historical financial results. Any forward-looking statements or future guidance would typically be contained within the accompanying press release (Exhibit 99.1) and should be reviewed carefully for any associated risks and uncertainties.
The information furnished in this Form 8-K, specifically the press release (Exhibit 99.1), is generally not considered 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means it does not carry the same level of liability as a formally filed document unless the company explicitly incorporates it into another filing.